40 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
18
Combining Elements from Two Antagonists of Formyl Peptide Receptor 2 Generates More Potent Peptidomimetic Antagonists.
University of Copenhagen
27
Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
University of Warsaw
12
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
University of Bari Aldo Moro
2
Pachymodulin, a new functional formyl peptide receptor 2 peptidic ligand isolated from frog skin has Janus-like immunomodulatory capacities.
Sorbonne University
16
6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
Universita Degli Studi Di Firenze
5
The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.
Monash University
87
Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Queen Mary University of London
28
Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.
University of Bari Aldo Moro
25
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.
Bristol Myers Squibb
17
Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.
Queen Mary University of London
31
Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
Queen Mary University of London
42
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Kyorin Pharmaceutical
11
Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A
University College Dublin
86
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Shanghaitech University
47
Substituted Pyridazin-3(2 H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists.
Monash University
3
FPRL-1 Receptor Modulators May Provide Treatment for Inflammation.
Therachem Research Medilab (India)
16
Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
University of Bari Aldo Moro
9
Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof
Shaanxi Panlong Pharmaceutical
100
Aminocarbamoyl compounds for the treatment of viral infections
F. Hoffmann-La Roche
27
Sultam compound and application method thereof
Chai Tai Tianqing Pharmaceutical Group
59
Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof
Shanghai Haiyan Pharmaceutical Technology
28
Selective Bruton's tyrosine kinase inhibitor and use thereof
Hangzhou Hertz Pharmaceutical
2
α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
Merck Serono
5
Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-a converting enzyme (TACE/ADAM-17).
China Pharmaceutical University
25
Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
University of California
16
Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
Abbott Laboratories
13
Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).
University of Illinois At Chicago
17
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Bristol Myers Squibb